Menopause Treatment

Uncommon Menopause Symptoms That Deserve More Attention

Most women enter the menopause transition expecting hot flashes, night sweats, and irregular periods. Nobody warns you about the vertigo that hits when you roll over in bed, the vaginal changes that make sex feel like sandpaper, the sudden diarrhea that strikes after every meal, or the eczema patches that appear on skin that has been clear your entire life. Finding reliable menopause vertigo treatment options is just one piece of a much larger puzzle. These symptoms are not rare — they are just rarely discussed. Research published in 2024 in the journal Climacteric found that up to 60 percent of women experience at least one of these under-recognized symptoms during perimenopause, but fewer than 15 percent connect the symptom to menopause without help from a clinician. The connection is estrogen. Every one of these symptoms traces back to the same biological mechanism: estrogen receptors are not limited to your ovaries. They line your inner ear, your vaginal tissues, your gut wall, and your skin. When estrogen drops, those tissues change. Recognizing the pattern is the first step toward relief for the whole cluster.

The problem is that each of these symptoms points in a different medical direction individually. Vertigo sends you to an ENT or neurologist. Vaginal discomfort sends you to a gynecologist. Diarrhea sends you to a gastroenterologist. Eczema sends you to a dermatologist. You see four different specialists, pay four different copays, get four different diagnoses and four different treatment plans — and none of them ask about your menstrual cycle. The single unifying diagnosis is menopause, and the single unifying treatment is estrogen. The ELITE trial, published in the New England Journal of Medicine in 2012 but still the most rigorous study on early-versus-late HRT initiation, demonstrated that estrogen therapy started within six years of menopause improves multiple tissue outcomes simultaneously. The same principle applies to these lesser-known symptoms: estrogen addresses the root cause across all four systems at once.

Menopause Vertigo and Dizziness: The Inner Ear Connection

Estrogen receptors are present throughout the inner ear, specifically in the vestibular system that functions as your body’s internal gyroscope. When estrogen levels fluctuate during perimenopause or drop after menopause, the vestibular system becomes unstable. The result is vertigo — the sensation that the room is spinning — or a more general dizziness that women describe as feeling “off balance” or “like walking on a boat.” A 2024 study in the Brazilian journal Clinics examined the relationship between menopause and vestibular disorders and found that women in the menopausal transition were 3.2 times more likely to develop benign paroxysmal positional vertigo (BPPV) than premenopausal women of the same age. BPPV occurs when tiny calcium carbonate crystals called otoconia break loose from their normal position in the inner ear’s utricle and drift into the semicircular canals. Estrogen helps anchor these crystals in place. When estrogen falls, the crystals dislodge.

The distinguishing feature of menopause-related BPPV is that the vertigo episodes are brief — under 60 seconds — and triggered by specific head movements: rolling over in bed, looking up to a high shelf, bending forward to tie your shoes. The episodes can cluster for weeks, then disappear for months, then return when hormone levels shift again. The Epley maneuver, a series of head-positioning movements that physically reposition the loose crystals, resolves BPPV in 80 to 90 percent of cases within one to three sessions with a vestibular physical therapist. Dr. Shin Beh, director of the Beh Center for Vestibular and Migraine Disorders in Irving, Texas, told the Vestibular Disorders Association in 2025 that “the recurrence rate of BPPV in perimenopausal women is twice that of age-matched men, and the reason is almost certainly hormonal. Treating the crystals without addressing the hormonal environment means the crystals will likely fall out again.” For women with recurrent BPPV who are otherwise candidates for HRT, transdermal estradiol appears to reduce the frequency of crystal dislodgment episodes. The same 2024 Clinics review reported that women on transdermal estrogen had fewer balance-related symptoms than women on no hormones, though the effect was modest — a 30 percent reduction in episode frequency over six months.

Not all menopause-related dizziness is BPPV. Vestibular migraine — migraine without headache that presents as vertigo — is the second most common cause and follows a different pattern: episodes last longer (minutes to hours rather than seconds), are not triggered by specific head movements, and are often accompanied by nausea and sensitivity to light. The 2024-2026 MsFLASH Network studies at the University of Washington are currently investigating whether low-dose estrogen therapy reduces vestibular migraine frequency in perimenopausal women, with results expected in late 2026. For detailed guidance on the full spectrum of menopause-related dizziness, read the menopause dizziness article.

Genitourinary Syndrome of Menopause: The Umbrella Term Your Doctor Should Be Using

Genitourinary Syndrome of Menopause — GSM — is the medical term for the constellation of vaginal, vulvar, and urinary symptoms caused by estrogen loss. It affects 50 to 70 percent of postmenopausal women, according to a 2025 consensus statement from the International Society for the Study of Women’s Sexual Health and NAMS. The syndrome includes vaginal dryness (the best-known symptom), but also vulvar burning and itching, urinary urgency and frequency, recurrent urinary tract infections, and painful sex. GSM is progressive — it does not improve on its own and typically worsens over time if untreated. Yet a 2024 survey in Menopause journal found that only 12 percent of women with GSM symptoms had received a formal diagnosis from their clinician. The rest were offered lubricants or told to “use it or lose it.”

The treatment ladder for GSM is well established and works in stages. First-line treatment for mild symptoms is over-the-counter vaginal moisturizers applied regularly (RepHresh, Replens) combined with water-based lubricants for sexual activity. For moderate symptoms, low-dose vaginal estrogen therapy — either as cream (Estrace, generic estradiol cream 0.01 percent), a tablet (Vagifem, generic estradiol tablet 10 mcg), or a ring (Estring, Femring) — is the gold standard and resolves symptoms in 85 to 95 percent of women within 8 to 12 weeks. For women who cannot or will not use estrogen, ospemifene (Osphena) is an oral selective estrogen receptor modulator approved by the FDA specifically for GSM-related dyspareunia. The phase 3 OSPHENA trials, published in 2023 in the Journal of Sexual Medicine, showed that 60 mg of ospemifene daily improved vaginal pH, increased superficial cells on vaginal cytology, and reduced pain scores by 50 to 60 percent over 12 weeks. For severe or refractory GSM, fractional CO2 laser therapy — marketed under names like MonaLisa Touch — has emerged as a third-line option. A 2025 systematic review in the Journal of Minimally Invasive Gynecology analyzed 23 studies and found that laser therapy improved GSM symptom scores by 40 to 70 percent, but the effect was temporary (12 to 18 months) and the evidence quality was limited by the absence of sham-controlled trials.

Here is the weird-specific detail that most women never hear: GSM can start as early as perimenopause, before periods have stopped entirely. The vaginal epithelium contains the highest concentration of estrogen receptors of any tissue in the body outside the reproductive organs themselves. The first sign is often subtle — a change in discharge, a feeling of tightness during sex, a recurrent UTI that culture-negative or resolves but returns within weeks. A 2024 study from the University of Michigan found that women in late perimenopause had significant declines in vaginal maturation index — a measure of epithelial health — before they reported any GSM symptoms at all. The tissue changes precede the symptoms by an average of 18 to 24 months. The broader discussion of menopause vaginal health covers GSM in more depth, including the full treatment protocol for each stage.

Menopause Diarrhea: The Digestive Side Nobody Talks About

The gut is one of the most densely estrogen-receptor-rich tissues in the body, yet the connection between menopause and diarrhea is almost never mentioned in standard menopause education. Approximately 90 percent of the body’s serotonin is produced in the gut, not the brain, and serotonin is a major regulator of bowel motility. Estrogen modulates the expression of the serotonin transporter SERT in the colonic epithelium. When estrogen drops, SERT expression decreases, more serotonin remains active in the gut wall, and transit time accelerates. The result is loose, urgent stools that can appear as early as perimenopause. A 2023 study in the journal Menopause analyzed data from 1,800 women in the Study of Women’s Health Across the Nation (SWAN) and found that women moving from premenopause to early perimenopause had a 40 percent increase in the likelihood of reporting frequent diarrhea compared to women who remained premenopausal. The finding held after controlling for diet, stress, antidepressant use, and body mass index.

For women who already have irritable bowel syndrome, menopause can amplify symptoms dramatically. The same estrogen fluctuation that triggers hot flashes also affects the enteric nervous system, and women with IBS are particularly sensitive to hormonal shifts. A 2025 clinical review in Neurogastroenterology and Motility examined the overlap between menopause and IBS and found that 46 percent of women with IBS reported worsening of bowel symptoms during the menopausal transition, with diarrhea-predominant and mixed-pattern IBS worsening more than constipation-predominant IBS. Small intestinal bacterial overgrowth — SIBO — is also more common after menopause. Estrogen supports the migrating motor complex, the wave-like contractions that sweep bacteria out of the small intestine between meals. When estrogen drops, the migrating motor complex slows, and bacteria can accumulate in the small intestine where they do not belong, causing bloating, gas, and diarrhea that does not respond to standard IBS treatments.

The three-step approach for menopause-related diarrhea starts with ruling out organic causes — coeliac disease, inflammatory bowel disease, and bile acid malabsorption — through blood tests (tTg-IgA, CRP, calprotectin) and stool tests. If those are negative, a six-week low-FODMAP diet trial identifies dietary triggers. If neither testing nor diet change explains the diarrhea, systemic HRT is the logical next treatment. A 2024 clinical audit from the Menopause Clinic at St. Thomas’ Hospital in London, published in Post Reproductive Health, followed 18 women with new-onset diarrhea-predominant IBS during perimenopause and found that 12 of the 18 reported complete resolution of bowel symptoms within three months of starting transdermal estradiol with micronized progesterone. For women whose diarrhea is accompanied by bloating and gas, the menopause digestion article covers dietary modifications that help, and the menopause diet page provides the full food framework.

Menopause Eczema and Skin Inflammation: The Collagen Connection

Estrogen plays three critical roles in skin health. It stimulates collagen production — the structural protein that gives skin its firmness and elasticity. It increases the synthesis of ceramides and hyaluronic acid, which form the skin’s moisture barrier — the stratum corneum. And it regulates the immune response in skin tissue, suppressing the inflammatory signals that drive eczema. When estrogen drops during menopause, all three mechanisms falter. Collagen production declines by roughly 30 percent in the first five years after the final menstrual period, according to a 2022 systematic review in Maturitas. The stratum corneum becomes drier and more permeable, allowing irritants to penetrate more easily. The immune regulation becomes less precise, and the skin mounts inflammatory responses to stimuli that previously caused no reaction. The result is a condition that presents identically to atopic eczema: red, dry, itchy patches on the face, neck, hands, and the flexural areas inside the elbows and knees.

A 2022 study in the British Journal of Dermatology analyzed data from over 12,000 women in the UK Biobank and found that the onset of perimenopause increased the risk of developing new-onset eczema by 60 percent compared to premenopausal women of the same age. The eczema that emerges in menopause differs from childhood eczema in two important ways. First, it often appears in women who have never had eczema before — it is a new immune pattern, not a flare of an old one. Second, it responds poorly to standard emollients and over-the-counter hydrocortisone because the root cause is hormonal, not allergic. A 2024 review in the journal Dermatology and Therapy examined 14 studies of HRT for skin health and found that women using systemic estrogen — particularly transdermal estradiol — showed significant improvement in skin hydration, barrier integrity, and eczema severity scores within three months. Topical estrogen cream applied directly to eczema patches has also shown promise: a small 2023 trial found that 0.01 percent estradiol cream applied twice daily produced visible improvement in 68 percent of participants with facial eczema after eight weeks. The menopause skin changes article covers the full picture of estrogen’s effects on skin, and the natural menopause treatment page includes dietary approaches that support skin barrier function.

Why These Symptoms Cluster and What to Do About It

The four symptoms in this article — vertigo, GSM, diarrhea, and eczema — share a common trigger: estrogen withdrawal. They often appear together or in sequence during perimenopause, and treating the underlying hormonal shift with systemic HRT frequently improves multiple symptoms at once. The ELITE trial and the KEEPS trial both demonstrated that early initiation of estrogen therapy produces benefits across multiple organ systems, and the same principle applies to these less common symptoms. A woman who starts transdermal estradiol for hot flashes may find that her vertigo episodes stop, her vaginal dryness resolves, her bowel movements normalize, and her eczema clears — all without separate treatments for each symptom. That is not a coincidence. It is the predictable result of restoring estrogen to tissues that have been deprived of it.

Of course, not every woman can take HRT. For women with a history of estrogen-sensitive breast cancer, cardiovascular disease, or a strong family history of thromboembolism, non-hormonal options exist for each symptom individually:

• Vertigo: The Epley maneuver for BPPV, meclizine (Antivert) or betahistine for acute episodes, and vestibular rehabilitation therapy for persistent imbalance.
• GSM: Ospemifene (Osphena) 60 mg daily for dyspareunia, vaginal moisturizers (Replens, Revaree) for dryness, and vaginal DHEA (prasterone/Intrarosa) for women who cannot use estrogen.
• Diarrhea: Low-FODMAP diet for 4 to 6 weeks to identify triggers, soluble fiber supplements (psyllium), and bile acid sequestrants if bile acid malabsorption is confirmed.
• Eczema: Topical corticosteroids (triamcinolone 0.1 percent) for acute flares, calcineurin inhibitors (tacrolimus, pimecrolimus) for sensitive areas, and ceramide-rich moisturizers for maintenance.

The key insight is that estrogen withdrawal should be considered the most likely cause before chasing separate diagnoses for each symptom. If you are in perimenopause and experiencing two or more of these symptoms, HRT is a reasonable starting point — provided you have no contraindications — and separate specialist referrals are a backup plan.

The menopause treatment guide covers the full range of options for each symptom mentioned here. The menopause symptoms page provides the complete list of recognized symptoms with prevalence data, and the menopause quiz can help you identify which stage of the transition you are in. For all symptoms and treatment paths, start at menopause treatment.